Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303)

Abstract

Background

The aim of this study was to explore the efficacy and safety of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer with modified dose reduction criteria by which the doses were manipulated earlier.

Methods

Gastric cancer patients who developed progression during the fluoropyrimidine-containing first-line chemotherapy were assigned to receive nab-paclitaxel (260 mg/m2) by triweekly administration. Dose reduction was regulated according to predefined toxicity criteria which included neutropenia less than 1000/mm3 and/or peripheral sensory neuropathy of grade 2 or more. The primary endpoint was progression-free survival.

Results

A total of 50 patients were enrolled, 47 of whom were eligible for efficacy analyses. The median number of treatment cycles and relative dose intensity given per patient was four (range 1–25), and 90% (range 60–100). Of total administration throughout the trial of 280 cycles, dose reduction was required in 50 cycles. The median progression-free survival was 3.5 months (95% confidence interval 2.5–4.4) that met the primary endpoint. The median overall survival was 9.0 months (95% confidence interval 6.8–11.8), overall response rate was 16% (95% confidence interval 2–30), and disease control rate was 72% (95% confidence interval 54–90). The median time to treatment failure was 3.5 months (95% confidence interval 2.5–4.4). Adverse events of grade 3 or worse included neutropenia in 49%, and peripheral sensory neuropathy in 11%. Febrile neutropenia occurred only in one patient (2%).

Conclusion

The modified dose reduction criteria for triweekly administration of nab-paclitaxel resulted in decreased incidence of severe peripheral sensory neuropathy without decline in efficacy.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    Globocan (2018) https://globocan.iarc.fr Accessed 1 Oct 2019

  2. 2.

    Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221

    CAS  Article  Google Scholar 

  3. 3.

    Wilke H, Muro K, Van Cutsem E et al (2014) RAINBOW study group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235

    CAS  Article  Google Scholar 

  4. 4.

    Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461–2471

    CAS  Article  Google Scholar 

  5. 5.

    Yamada Y, Boku N, Mizusawa J et al (2019) Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 4:501–510

    Article  Google Scholar 

  6. 6.

    Hironaka S, Ueda S, Yasui H et al (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31:4438–4444

    CAS  Article  Google Scholar 

  7. 7.

    Sparreboom A, Scripture CD, Trieu V et al (2005) Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 11:4136–4143

    CAS  Article  Google Scholar 

  8. 8.

    Desai N, Trieu V, Yao Z et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–1324

    CAS  Article  Google Scholar 

  9. 9.

    Sasaki Y, Nishina T, Yasui H et al (2014) Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci 105:812–817

    CAS  Article  Google Scholar 

  10. 10.

    Shitara K, Takashima A, Fujitani K et al (2017) Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2:277–287

    Article  Google Scholar 

  11. 11.

    Sato S, Kunisaki C, Tanaka Y et al (2018) A phase II study of tri-weekly low-dose nab-paclitaxel chemotherapy for patients with advanced gastric cancer. Anticancer Res 38:6911–6917

    Article  Google Scholar 

  12. 12.

    Fukuchi M, Mochiki E, Ishiguro T et al (2016) Efficacy of nab-paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Anticancer Res 36:6699–6703

    CAS  Article  Google Scholar 

  13. 13.

    Cavaletti G, Marmiroli P (2010) Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 6:657–666

    Article  Google Scholar 

  14. 14.

    Postma TJ, Heimans JJ (2000) Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11:509–513

    CAS  Article  Google Scholar 

  15. 15.

    Velasco R, Bruna J (2015) Taxane-induced peripheral neurotoxicity. Toxics 3:152–169

    CAS  Article  Google Scholar 

  16. 16.

    Kim JT, Sun CL, Mailey B et al (2010) Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol 21:152–160

    CAS  Article  Google Scholar 

Download references

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Affiliations

Authors

Contributions

Conception and design: DK, YK, Collection and assembly of data: All author, Data analysis and interpretation: DK, MA, YK, Manuscript writing: All authors, Final approval of manuscript: All authors.

Corresponding author

Correspondence to Daisuke Kobayashi.

Ethics declarations

Conflict of interest

Yasuhiro Kodera has received grants and personal fees from Taiho Pharmaceutical outside the submitted work. All other authors have no relevant disclosures with regard to this paper to declare.

Human rights statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.

Informed consent

Informed consent or substitute for it was obtained from all patients for their being included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kobayashi, D., Mochizuki, Y., Torii, K. et al. Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303). Int J Clin Oncol (2020). https://doi.org/10.1007/s10147-020-01724-8

Download citation

Keywords

  • Gastric cancer
  • Nab-paclitaxel
  • Peripheral sensory neuropathy